Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Cash and Cash Equivalents [Table Text Block]

	DECEMBER 31, 2016		SEPTEMBER 30, 2017
Biolargo, Inc. and wholly owned subsidiaries	$	1,671,857	$	431,034
Clyra Medical Technologies, Inc.		238,296		820,917
Total	$	1,910,153	$	1,251,951